Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1993 Mar;108(3):793–800. doi: 10.1111/j.1476-5381.1993.tb12880.x

Higher potency of RP 67580, in the mouse and the rat compared with other nonpeptide and peptide tachykinin NK1 antagonists.

J C Beaujouan 1, E Heuillet 1, F Petitet 1, M Saffroy 1, Y Torrens 1, J Glowinski 1
PMCID: PMC1908019  PMID: 7682138

Abstract

1. This study was undertaken to compare the potency and selectivity of the nonpeptide (RP 67580, (+/-)-CP-96,345 and its chloro-derivative [(+/-)-cis-3-(2-chlorobenzylamino)-2-benzhydrylquinuclidine] (CP-C1)) and peptide (GR 71,251 and spantide) neurokinin1 (NK1) antagonists in mouse and rat preparations. 2. Among the NK1 antagonists tested, RP 67580 was the most potent in inhibiting the specific binding of [125I]-Bolton Hunter substance P ([125I]-BHSP) to crude synaptosomes from the rat brain (Ki: 2.9 nM). (+/-)-CP-96,345 was about ten fold less potent (Ki: 31 nM) than RP 67580 while other compounds exhibited even less affinity. 3. All NK1 antagonists inhibit competitively the activation of phospholipase C by [Pro9]substance P ([Pro9]SP) in cultured cortical astrocytes from the newborn mouse, a preparation rich in NK1 receptors but devoid of NK2 and NK3 receptors. pA2 values for the most potent compounds, RP 67580 and (+/-)-CP-96,345, were 8.28 and 7.08 respectively. When used alone, all antagonists showed some agonist activity at 10(-5) M, except spantide which was already effective at 10(-6) M. 4. An excellent correlation was found between the potency of the NK1 antagonists in blocking the stimulation by [Pro9]SP of phosphoinositide breakdown in cortical astrocytes and in inhibiting [125I]-BHSP specific binding to rat brain synaptosomes. 5. As shown on single cells by use of the Indo-1 microfluorometric method, RP 67580 (10(-7) M) prevented reversibly the elevation of cytosolic calcium concentration induced by [Pro9]SP (10(-8) M) in cultured cortical astrocytes. 6. Several experiments indicated that the antagonists were highly selective for NK1 receptors.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
793

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beaujouan J. C., Saffroy M., Petitet F., Torrens Y., Glowinski J. Neuropeptide K, scyliorhinin I and II: new tools in the tachykinin receptor field. Eur J Pharmacol. 1988 Jul 7;151(2):353–354. doi: 10.1016/0014-2999(88)90826-6. [DOI] [PubMed] [Google Scholar]
  2. Beaujouan J. C., Teutsch B., Saffroy M., Petitet F., Torrens Y., Glowinski J. NK-1 receptors are the only class of tachykinin receptors found on mouse cortical astrocytes. Peptides. 1991 Jul-Aug;12(4):813–820. doi: 10.1016/0196-9781(91)90139-g. [DOI] [PubMed] [Google Scholar]
  3. Beaujouan J. C., Torrens Y., Viger A., Glowinski J. A new type of tachykinin binding site in the rat brain characterized by specific binding of a labeled eledoisin derivative. Mol Pharmacol. 1984 Sep;26(2):248–254. [PubMed] [Google Scholar]
  4. Bergström L., Beaujouan J. C., Torrens Y., Saffroy M., Glowinski J., Lavielle S., Chassaing G., Marquet A., D'Orleans-Juste P., Dion S. 3H-neurokinin A labels a specific tachykinin-binding site in the rat duodenal smooth muscle. Mol Pharmacol. 1987 Dec;32(6):764–771. [PubMed] [Google Scholar]
  5. Berridge M. J., Downes C. P., Hanley M. R. Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands. Biochem J. 1982 Sep 15;206(3):587–595. doi: 10.1042/bj2060587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bristow D. R., Curtis N. R., Suman-Chauhan N., Watling K. J., Williams B. J. Effects of tachykinins on inositol phospholipid hydrolysis in slices of hamster urinary bladder. Br J Pharmacol. 1987 Jan;90(1):211–217. doi: 10.1111/j.1476-5381.1987.tb16842.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Constantine J. W., Lebel W. S., Woody H. A. Inhibition of tachykinin-induced hypotension in dogs by CP-96,345, a selective blocker of NK-1 receptors. Naunyn Schmiedebergs Arch Pharmacol. 1991 Oct;344(4):471–477. doi: 10.1007/BF00172588. [DOI] [PubMed] [Google Scholar]
  8. Delumeau J. C., Petitet F., Cordier J., Glowinski J., Prémont J. Synergistic regulation of cytosolic Ca2+ concentration in mouse astrocytes by NK1 tachykinin and adenosine agonists. J Neurochem. 1991 Dec;57(6):2026–2035. doi: 10.1111/j.1471-4159.1991.tb06418.x. [DOI] [PubMed] [Google Scholar]
  9. Folkers K., Håkanson R., Hörig J., Xu J. C., Leander S. Biological evaluation of substance P antagonists. Br J Pharmacol. 1984 Oct;83(2):449–456. doi: 10.1111/j.1476-5381.1984.tb16506.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Freedman J., Hökfelt T., Post C., Brodin E., Sundström E., Jonsson G., Terenius L., Leander S., Fischer J. A., Verhofstad A. Immunohistochemical and behavioral analysis of spinal lesions induced by a substance P antagonist and protection by thyrotropin releasing hormone. Exp Brain Res. 1989;74(2):279–292. doi: 10.1007/BF00248861. [DOI] [PubMed] [Google Scholar]
  11. Garret C., Carruette A., Fardin V., Moussaoui S., Peyronel J. F., Blanchard J. C., Laduron P. M. Pharmacological properties of a potent and selective nonpeptide substance P antagonist. Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10208–10212. doi: 10.1073/pnas.88.22.10208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gerard N. P., Eddy R. L., Jr, Shows T. B., Gerard C. The human neurokinin A (substance K) receptor. Molecular cloning of the gene, chromosome localization, and isolation of cDNA from tracheal and gastric tissues. J Biol Chem. 1990 Nov 25;265(33):20455–20462. [PubMed] [Google Scholar]
  13. Gerard N. P., Eddy R. L., Jr, Shows T. B., Gerard C. The human neurokinin A (substance K) receptor. Molecular cloning of the gene, chromosome localization, and isolation of the cDNA from tracheal and gastric tissues. J Biol Chem. 1991 Jan 15;266(2):1354–1354. [PubMed] [Google Scholar]
  14. Gitter B. D., Waters D. C., Bruns R. F., Mason N. R., Nixon J. A., Howbert J. J. Species differences in affinities of non-peptide antagonists for substance P receptors. Eur J Pharmacol. 1991 May 17;197(2-3):237–238. doi: 10.1016/0014-2999(91)90532-u. [DOI] [PubMed] [Google Scholar]
  15. Grynkiewicz G., Poenie M., Tsien R. Y. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem. 1985 Mar 25;260(6):3440–3450. [PubMed] [Google Scholar]
  16. Hökfelt T., Vincent S., Hellsten L., Rosell S., Folkers K., Markey K., Goldstein M., Cuello C. Immunohistochemical evidence for a "neurotoxic" action of (D-Pro2, D-Trp7,9)-substance P, an analogue with substance P antagonistic activity. Acta Physiol Scand. 1981 Dec;113(4):571–573. doi: 10.1111/j.1748-1716.1981.tb06943.x. [DOI] [PubMed] [Google Scholar]
  17. Kage R., McGregor G. P., Thim L., Conlon J. M. Neuropeptide-gamma: a peptide isolated from rabbit intestine that is derived from gamma-preprotachykinin. J Neurochem. 1988 May;50(5):1412–1417. doi: 10.1111/j.1471-4159.1988.tb03024.x. [DOI] [PubMed] [Google Scholar]
  18. Krause J. E., Hershey A. D., Dykema P. E., Takeda Y. Molecular biological studies on the diversity of chemical signalling in tachykinin peptidergic neurons. Ann N Y Acad Sci. 1990;579:254–272. doi: 10.1111/j.1749-6632.1990.tb48367.x. [DOI] [PubMed] [Google Scholar]
  19. Lavielle S., Chassaing G., Julien S., Marquet A., Bergström L., Beaujouan J. C., Torrens Y., Glowinski J. Specific recognition of SP or NKB receptors by analogues of SP substituted at positions 8 and 9. Eur J Pharmacol. 1986 Jun 24;125(3):461–462. doi: 10.1016/0014-2999(86)90804-6. [DOI] [PubMed] [Google Scholar]
  20. Lavielle S., Chassaing G., Ploux O., Loeuillet D., Besseyre J., Julien S., Marquet A., Convert O., Beaujouan J. C., Torrens Y. Analysis of tachykinin binding site interactions using constrained analogues of tachykinins. Biochem Pharmacol. 1988 Jan 1;37(1):41–49. doi: 10.1016/0006-2952(88)90753-8. [DOI] [PubMed] [Google Scholar]
  21. Maggio J. E. Tachykinins. Annu Rev Neurosci. 1988;11:13–28. doi: 10.1146/annurev.ne.11.030188.000305. [DOI] [PubMed] [Google Scholar]
  22. McLean S., Ganong A. H., Seeger T. F., Bryce D. K., Pratt K. G., Reynolds L. S., Siok C. J., Lowe J. A., 3rd, Heym J. Activity and distribution of binding sites in brain of a nonpeptide substance P (NK1) receptor antagonist. Science. 1991 Jan 25;251(4992):437–439. doi: 10.1126/science.1703324. [DOI] [PubMed] [Google Scholar]
  23. Nakanishi S. Mammalian tachykinin receptors. Annu Rev Neurosci. 1991;14:123–136. doi: 10.1146/annurev.ne.14.030191.001011. [DOI] [PubMed] [Google Scholar]
  24. Petitet F., Beaujouan J. C., Saffroy M., Torrens Y., Chassaing G., Lavielle S., Besseyre J., Garret C., Carruette A., Glowinski J. Further demonstration that [Pro9]-substance P is a potent and selective ligand of NK-1 tachykinin receptors. J Neurochem. 1991 Mar;56(3):879–889. doi: 10.1111/j.1471-4159.1991.tb02004.x. [DOI] [PubMed] [Google Scholar]
  25. Petitet F., Saffroy M., Torrens Y., Lavielle S., Chassaing G., Loeuillet D., Glowinski J., Beaujouan J. C. Possible existence of a new tachykinin receptor subtype in the guinea pig ileum. Peptides. 1992 Mar-Apr;13(2):383–388. doi: 10.1016/0196-9781(92)90125-m. [DOI] [PubMed] [Google Scholar]
  26. Regoli D., Drapeau G., Dion S., D'Orléans-Juste P. Receptors for substance P and related neurokinins. Pharmacology. 1989;38(1):1–15. doi: 10.1159/000138512. [DOI] [PubMed] [Google Scholar]
  27. Rouissi N., Gitter B. D., Waters D. C., Howbert J. J., Nixon J. A., Regoli D. Selectivity and specificity of new, non-peptide, quinuclidine antagonists of substance P. Biochem Biophys Res Commun. 1991 Apr 30;176(2):894–901. doi: 10.1016/s0006-291x(05)80270-0. [DOI] [PubMed] [Google Scholar]
  28. Snider R. M., Constantine J. W., Lowe J. A., 3rd, Longo K. P., Lebel W. S., Woody H. A., Drozda S. E., Desai M. C., Vinick F. J., Spencer R. W. A potent nonpeptide antagonist of the substance P (NK1) receptor. Science. 1991 Jan 25;251(4992):435–437. doi: 10.1126/science.1703323. [DOI] [PubMed] [Google Scholar]
  29. Snider R. M., Longo K. P., Drozda S. E., Lowe J. A., 3rd, Leeman S. E. Effect of CP-96,345, a nonpeptide substance P receptor antagonist, on salivation in rats. Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10042–10044. doi: 10.1073/pnas.88.22.10042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Takeda Y., Chou K. B., Takeda J., Sachais B. S., Krause J. E. Molecular cloning, structural characterization and functional expression of the human substance P receptor. Biochem Biophys Res Commun. 1991 Sep 30;179(3):1232–1240. doi: 10.1016/0006-291x(91)91704-g. [DOI] [PubMed] [Google Scholar]
  31. Tatemoto K., Lundberg J. M., Jörnvall H., Mutt V. Neuropeptide K: isolation, structure and biological activities of a novel brain tachykinin. Biochem Biophys Res Commun. 1985 Apr 30;128(2):947–953. doi: 10.1016/0006-291x(85)90138-x. [DOI] [PubMed] [Google Scholar]
  32. Torrens Y., Daguet De Montety M. C., el Etr M., Beaujouan J. C., Glowinski J. Tachykinin receptors of the NK1 type (substance P) coupled positively to phospholipase C on cortical astrocytes from the newborn mouse in primary culture. J Neurochem. 1989 Jun;52(6):1913–1918. doi: 10.1111/j.1471-4159.1989.tb07276.x. [DOI] [PubMed] [Google Scholar]
  33. Viger A., Beaujouan J. C., Torrens Y., Glowinski J. Specific binding of a 125I-substance P derivative to rat brain synaptosomes. J Neurochem. 1983 Apr;40(4):1030–1039. doi: 10.1111/j.1471-4159.1983.tb08089.x. [DOI] [PubMed] [Google Scholar]
  34. Ward P., Ewan G. B., Jordan C. C., Ireland S. J., Hagan R. M., Brown J. R. Potent and highly selective neurokinin antagonists. J Med Chem. 1990 Jul;33(7):1848–1851. doi: 10.1021/jm00169a003. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES